Key
Points
- This study reports clinical outcome data on 76 patients with
platinum-resistant recurrent or metastatic head and neck squamous
carcinoma treated with nivolumab, making it the largest published
single centre case series of its kind.
- Radiotherapy was administered alongside systemic therapy with
nivolumab, defined as radiotherapy within 8 weeks of prior systemic
therapy, in 16 of 76 patients (21%).
- Nivolumab was continued following radiotherapy completion due to
ongoing clinical benefit from the drug in 9 of 16 patients (56%).
- Durable complete response following radio-immunotherapy was seen in 2
of the 9 patients (22%) who continued nivolumab subsequent to
radiotherapy.
- Indications for radiotherapy included symptom control (3 of 9),
oligoprogression (5 of 9) and incomplete response (1 of 9).